Search
forLearn
5 / 801 resultslearn pyrrolidone carboxylic acid
learn PTD-DBM
learn PTT-6®
learn APISCALP™
Research
5 / 1000+ results
research 1369 Terminalia chebula fruit extract from PSR™ technology demonstrates strong anti-aging and antioxidant properties
Terminalia chebula fruit extract has strong anti-aging and antioxidant effects.
research 1371 Impact of temperature on sprouted seeds in botanical extracts obtained with different extraction processes
Cold temperatures reduce sprouted seed extract yield, but PSR™ technology produces extracts with more beneficial compounds than conventional methods.
research Successful Treatment of Adalimumab-Induced Paradoxical Skin Reactions in Pustulotic Arthro-Osteitis With Guselkumab
Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.
research MARFATIA AWARD
The screening method effectively predicts psychosis, valproate use is linked to hair loss, and IDEAS is valid for assessing mental disorder disability.
research Removal of Mimosine from Leucaena leucocephala (Lam.) de Wit Seeds to Increase Their Benefits as Nutraceuticals
Using unsoaked seeds with 70% ethanol best removes mimosine from Leucaena seeds.
Community Join
5 / 1000+ resultscommunity I think I might have cured my hairloss
The user experienced severe dandruff and hair loss, trying various treatments including oils, vitamins, and minoxidil. They found success by simply dampening their scalp with water twice a day, which improved their hair's appearance and eliminated psoriasis.
community I have Post PP405 Syndrome(PPS). Should I start a foundation?
The conversation humorously discusses the fictional "Post PP405 Syndrome" and the idea of starting a foundation or cult around it. It mentions skepticism about the effectiveness of PP405 and jokes about future therapies.
community PP405 (Non) Update - Feb 2025
The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community The story of RU58841/ PSK3841
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.